12 results about "Antibody induction" patented technology

The present invention is directed to multispecific molecules that bind immunoglobulin and a recycling target. Binding immunoglobulin and a recycling target results in degradation of immunoglobulin and in certain embodiments recycling of the multispecific molecule. The multispecific molecules of the present invention are thought to be useful in the treatment of autoantibody-induced diseases.

To provide the use of a CBR1 agonist as an adjuvant and an adjuvant composition.SOLUTION: A compound represented by formula (1): Wherein R represents a cyclopropyl group or a 2-chloroethyl group. The antibody induction-promoting agent contains a compound represented by general formula (I) as an active ingredient.SELECTED DRAWING: None

In certain aspects the invention provides HIV-1 immunogens, including HIV-1 envelopes with optimized V2 loop for antibody induction.

The invention belongs to the field of medicinal chemistry and pharmacology, and relates to application of a novel glycolipid TLR2 agonist 13-C in preparation of vaccine adjuvants and anti-tumor treatment. The compound is excellent in human TLR2 agonist activity, EC50 reaches 2.2 nM, and the compound is simple in structure, easy to prepare and excellent in solubility and has industrial application potential. In a B16-OVA tumor model, the antibody induction capacity of the compound is superior to that of a positive control drug Diprovocim, and the anti-tumor activity of the compound is more remarkable; in addition, PD-L1 expression of tumor tissue can be effectively down-regulated, and a synergistic anti-tumor effect is generated with a PD-L1 monoclonal antibody Atezolizumab. Besides, 13-C and a vaccine adjuvant QS-21 are combined for use, so that a synergistic enhancement effect is achieved, the antibody titer induced by a vaccine can be remarkably improved, antibody subtypes are enriched, meanwhile, cellular immunity and humoral immunity response of an organism are stimulated, and the effect of dual immune activation is achieved.

The application discloses an ASFV dominant antigen epitope tandem recombinant protein, and an amino acid sequence of the ASFV dominant antigen epitope tandem recombinant protein is shown as SEQ ID NO:1, and belongs to the field of biology. The P54 and B602L proteins of the high immunogenicity region of the screened ASFV dominant antigen epitope are tandemly expressed according to the antibody induction efficiency in a pig group to obtain the recombinant protein. An ASFV indirect ELISA detection method is established by taking the recombinant protein as an antigen. The method has high accuracy, good specificity and high sensitivity, and has a large application prospect in the prevention and control of the ASF disease.

A structurally intact red blood cell membrane, a preparation method therefor and the use thereof. Defining components of a release solution to lyse red blood cells allows for mild conditions, and can release protein components such as hemoglobin inside the red blood cells, remove cell properties thereof, keep the integrity of the cytoskeleton thereof and the activity of surface antigens of the membrane, and retain key blood group antigens on the surface of the red blood cell membrane while keeping the complete structure of the red blood cell membrane, thus reducing the problem of antigenicity reduction caused by fragmentation of the red blood cell membrane. After the red blood cells are lysed, nanoparticles are coupled to the surface of the red blood cell membrane, thus visualizing the agglutination reaction of the red blood cell membrane under the induction of antibodies. Using a fixed procedure to preserve engineered red blood cell biomembranes can effectively avoid damage to the engineered red blood cell biomembrane caused by ice crystals, ensure that the antigenicity of the membranes is not affected, allow for long-term preservation at room temperature, and prolong the shelf life to two years or more.

In certain aspects the invention provides HIV-1 immunogens, including HIV-1 envelopes with optimized sequences for antibody induction. In some embodiments, the invention provides mRNA sequences of said HIV-1 immunogens.

The invention discloses a riemerella anatipestifer glucosamine oligosaccharide protein conjugate as well as a preparation method and application thereof, the glucosamine oligosaccharide protein conjugate is formed by connecting glucosamine oligosaccharide and carrier protein through a linking group, and the structural general formula of the glucosamine oligosaccharide protein conjugate is as shown in formula (III). The glucosamine oligoglycoprotein conjugate with a clear structure is prepared by utilizing a chemical synthesis method. An enzyme-linked immunosorbent assay experiment result shows that serum of a positive immune mouse and glucosamine oligosaccharides with different chain lengths have different recognition effects, and the glucosamine oligoglycoprotein conjugate can excite an antigen-specific IgG antibody with very high titer and an IgM antibody with high titer, induce a strong T-cell dependent protective immunoreaction, and can be used for preparing the immunosorbent assay kit. After immunization, serum can be obviously combined with inactivated riemerella anatipestifer. Therefore, the glucosamine oligosaccharide protein conjugate provided by the invention has relatively high application value in preparation of vaccines for resisting riemerella anatipestifer infection and drug development. In addition, the preparation steps are simple, and the yield is high.

The present invention addresses the problem of providing a novel therapeutic agent for treating patients with anti NMDAR encephalitis. Patients with an anti NMDAR encephalitis have a pathogenic anti-human NR1 antibody that induces internalization of NMDAR on cell surface. As a result, NMDAR function is weakened in the patients' brain. The present inventors found that the one-armed anti-human NR1 antibody according to the present invention binds to NR1 competitively with the pathogenic anti-human NR1 antibody and inhibits the internalization of NMDAR by the pathogenic anti-human NR1 antibody to thereby exhibit therapeutic effect on anti NMDAR encephalitis. Accordingly, the present invention provides the a one-armed anti-human NR1 antibody, a polynucleotide encoding the antibody, an expression vector containing the polynucleotide, a host cell transformed by the expression vector, a method for producing the antibody, a pharmaceutical composition comprising the antibody, a use of the antibody in the manufacture of the pharmaceutical composition, and a method for treating anti NMDAR encephalitis using the antibody.

In certain aspects the invention provides HIV-1 immunogens, including HIV-1 envelopes with optimized V2 loop for antibody induction.

The present invention relates to multispecific molecules that bind to immunoglobulins and recycling targets. Binding of the immunoglobulin to a recycling target results in degradation of the immunoglobulin and, in certain embodiments, recycling of the multispecific molecule. The multispecific molecules of the invention are believed to be useful in the treatment of autoantibody-induced diseases.

In certain aspects the invention provides HIV-1 immunogens, including HIV-1 envelopes with optimized sequences for antibody induction.